Geode Capital Management
JUNO

Geode Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Geode Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-768,667
Closed -$35.1M – 4118
2017
Q4 		$35.1M Buy
768,667
+74,519
+11% +$3.72M 0.01% 892
2017
Q3 		$31.1M Buy
694,148
+35,721
+5% +$1.22M 0.01% 932
2017
Q2 		$19.7M Buy
658,427
+63,291
+11% +$1.56M 0.01% 1195
2017
Q1 		$13.2M Buy
595,136
+48,516
+9% +$1.04M 0.01% 1444
2016
Q4 		$10.3M Buy
546,620
+39,611
+8% +$969K ﹤0.01% 1551
2016
Q3 		$15.2M Buy
507,009
+9,709
+2% +$302K 0.01% 1194
2016
Q2 		$19.1M Buy
497,300
+73,639
+17% +$3.06M 0.01% 978
2016
Q1 		$16.1K Buy
423,661
+17,205
+4% +$600K 0.01% 1057
2015
Q4 		$17.9M Buy
406,456
+13,748
+4% +$682K 0.01% 962
2015
Q3 		$16M Buy
392,708
+234,761
+149% +$10.3M 0.01% 1023
2015
Q2 		$8.42M Buy
157,947
+2,818
+2% +$150K ﹤0.01% 1536
2015
Q1 		$9.41M Buy
155,129
+135,265
+681% +$6.56M 0.01% 1433
2014
Q4 		$1.04M Buy
+19,864
New +$889K ﹤0.01% 2818

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Geode Capital Management's JUNO Position: Q1 2018 in Review

Geode Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 768,667 shares — an estimated $35.1M sold.

Geode Capital Management first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $35.1M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Geode Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Geode Capital Management sold 768,667 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $35.1M.
  • Geode Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Geode Capital Management's Juno Therapeutics, Inc. position peaked at $35.1M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Geode Capital Management's 13F filing for Q1 2018, filed 15 May 2018.